| Bioactivity | Emerfetamab (AMG 673) is a half-life extended bispecific T-cell engager that binds both CD33 and CD3. Emerfetamab redirects T cells toward CD33+ cells, leading to T-cell-mediated cytotoxicity against acute myeloid leukemia (AML) blasts[1]. |
| CAS | 2250261-27-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Marion Subklewe MD, et al. Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Blood. Volume 134, Supplement 1, 13 November 2019, Page 833 |